Flyte

Based in Minneapolis, Minnesota, Pelvital develops Flyte, an in-home medical device that delivers mechanotherapy to treat stress urinary incontinence and strengthen pelvic floor muscles in women. The privately held medtech company targets an addressable market of approximately 15 to 16 million affected women in the United States by selling its products directly to consumers and through clinical partnerships. The intravaginal device is designed to enhance traditional Kegel exercises and officially received clearance from the United States Food and Drug Administration in August 2020 following extensive clinical trials. Operating with a small core team of 4 employees, the organization is currently led by Chief Executive Officer Lydia Zeller and has received early financial backing from venture capital investors including Boomerang Ventures. Pelvital was originally founded in 2016 by an international team including Dale Wahlstrom, Gunnar Leivseth, and Ole Olsen.